Molecular Profile Detail

Profile Name BRAF wild-type KRAS wild-type NRAS wild-type
Gene Variant Detail

BRAF wild-type (no effect)

KRAS wild-type (no effect)

NRAS wild-type (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Cetuximab + Irinotecan Guideline Actionable Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Irinotecan + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Guideline Actionable Erbitux (cetuximab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Guideline Actionable Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colorectal cancer predicted - sensitive Cetuximab + Fluorouracil + Irinotecan + Leucovorin Phase II Actionable In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930). 29450468
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Cetuximab + Fluorouracil + Irinotecan + Leucovorin Guideline Actionable Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colorectal cancer predicted - sensitive Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Phase II Actionable In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930). 29450468
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Cetuximab + Fluorouracil + Irinotecan + Leucovorin Guideline Actionable Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Guideline Actionable Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colon cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Irinotecan + Panitumumab Guideline Actionable Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Cetuximab + Irinotecan Guideline Actionable Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
BRAF wild-type KRAS wild-type NRAS wild-type colorectal cancer predicted - sensitive Cetuximab + Irinotecan Phase II Actionable In a Phase II trial, Erbitux (cetuximab) and Camptosar (irinotecan) rechallenge resulted in a response rate of 21% (6/28, 6 partial responses) and a disease control rate of 54% (15/28) in RAS and BRAF wild-type colorectal cancer patients that acquired resistance to first-line cetuximab and irinotican-based therapy, patients with wild-type RAS in ctDNA at baseline achieved longer median progression-free survival (4.0 vs 1.9 mo, HR=0.44, p=0.03) compared to those with mutant RAS (PMID: 30476968; NCT02296203). 30476968
BRAF wild-type KRAS wild-type NRAS wild-type rectum cancer sensitive Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Guideline Actionable Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02399943 Phase II Panitumumab + Trametinib A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer Recruiting
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Ipilimumab + Nivolumab Crizotinib Palbociclib Sunitinib Olaparib Cetuximab TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting